Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Clinical Pharmacokinetics · 2023-10 · 62 (10) · 1333-1364
DOI: 10.1007/s40262-023-01293-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 16.08.2023. Verfasst von Maud B A van der Kleij und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlan…. Hauptthemen laut MEDLINE: Drug Monitoring. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits all' regimen is still often used. In the meantime, relationships between exposure-response and exposure-toxicity have been established for several KIs, so this regimen could lead to unnecessary toxicity and suboptimal efficacy. Dose adjustments based on measured systemic pharmacokinetic levels-i.e., therapeutic drug monitoring (TDM)-could therefore improve treatment efficacy and reduce the incidence of toxicities. Therefore, the aim of this comprehensive review is to give an overview of the available evidence for TDM for the 77 FDA/EMA kinase inhibitors currently approved (as of July 1st, 2023) used in hematology and oncology. We elaborate on exposure-response and exposure-toxicity relationships for these kinase inhibitors and provide practical recommendations for TDM and discuss corresponding pharmacokinetic targets when possible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. m.vd.kleij@nki.nl.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. m.vd.kleij@nki.nl.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
ORCID-Profile: Maud B A van der Kleij, Niels A D Guchelaar, Ron H J Mathijssen, Jurjen Versluis, Alwin D R Huitema, Stijn L W Koolen, Neeltje Steeghs
Zitieren
APA
van der Kleij, M. B. A., Guchelaar, N. A. D., Mathijssen, R. H. J., Versluis, J., Huitema, A. D. R., Koolen, S. L. W., & Steeghs, N. (2023). Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clinical Pharmacokinetics, 62(10), 1333-1364. https://doi.org/10.1007/s40262-023-01293-9
Vancouver
van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, et al. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clinical Pharmacokinetics. 2023;62(10):1333-1364. doi:10.1007/s40262-023-01293-9
BibTeX
@article{vanderKleij2023,
author = {van der Kleij, Maud B A and Guchelaar, Niels A D and Mathijssen, Ron H J and Versluis, Jurjen and Huitema, Alwin D R and Koolen, Stijn L W and Steeghs, Neeltje},
title = {Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology},
journal = {Clinical Pharmacokinetics},
year = {2023},
volume = {62},
number = {10},
pages = {1333--1364},
doi = {10.1007/s40262-023-01293-9}
}
EUVIMED